CD48 (CD48 Molecule)

Analysis of the expression of HML-2 and its association with CpG methylation contributes to a comprehensive interpretation of the CRC pathogenesis mechanisms.

Post-hoc power analysis showed 82% power to detect AUC differences ≥0.15. Integration of CD4 with PCT and Lactate markedly improved diagnostic accuracy in this cohort; however, given the limited number of bacteremic episodes, these findings should be considered exploratory and require external validation in larger, multicenter studies before clinical implementation.

Incorporating these markers in combination with established aberrant markers can enhance the identification of LSCs and help distinguish them from HSCs in both CD34 + and CD34- AML. Our findings support the use of an expanded combinatorial marker panel and warrants its further evaluation in a larger AML cohort, particularly in the context of measurable residual disease (MRD) assessment, prognostication and correlation with treatment response and survival outcomes.

CD48 represents a novel immune checkpoint on TAMs critical for HCC progression and immunotherapy resistance. Targeting CD48 may overcome immunosuppression and increase therapeutic efficacy in HCC.

To investigate this question, we used a knock-in mouse that constitutively expresses a Calr frameshift allele and introduced conditional Ezh2 deletion triggered by tamoxifen...Short-term colony assays showed that inhibition of PPARγ modestly increased the anti-proliferative effect of cytarabine on AML-derived stem and progenitor cells, suggesting a possible reliance on FAO...At a non-critical stage, peripheral counts remain near-normal while bone marrow HSPC compartments are already distorted. AML-like, but not sMF-like, Flk2- CD48+ LSK cells transmit leukemia and display enhanced fatty-acid-oxidation signatures, suggesting a distinct, potentially targetable metabolic bias.

These findings were further corroborated by our single-cell RNA data and multiplex immunohistochemistry results, which provided additional substantiation for the observed interactions. These observations regarding the interaction between the tumor microenvironment and nasopharyngeal carcinoma have significant clinical implications for the future treatment of NPC.

Our findings validate GDF15 targeting as a viable strategy to overcome checkpoint inhibitor resistance in HCC. The GFRAL-Fc fusion protein demonstrates multimodal therapeutic benefits through metabolic regulation and immune remodeling, providing a clinically translatable approach to optimize PD-1-based regimens. This study addresses critical gaps in current HCC management and warrants further clinical validation.

Parallel pre-clinical studies validate 2B4 blockade as a rational combinatorial strategy to reinvigorate exhausted CD8+ T and NK cells, while soluble CD48 emerges as a dynamic biomarker of disease activity. Collectively, these insights redefine 2B4 as a systems-level integrator of immune homeostasis and a tractable precision-immunotherapy node whose therapeutic manipulation can rebalance immunity across infection, cancer, and pregnancy.

This autophagy-related gene signature provides a reliable prognostic tool for MM, highlighting immune dysregulation and therapeutic resistance mechanisms. Its integration with clinical parameters enhances risk stratification and treatment planning.

Our data suggest that the rapid co-culture system of iRGD-modified CIML NK&Ac-T cells used for adoptive cell transfer demonstrates potent anti-tumor effects in gastric cancer. This approach is time-efficient and cost-saving, with potential for broader clinical application compared with conventional NK cell therapies.

Using peripheral blood biomarkers, we characterized immune subtypes of osteosarcoma, and developed a predictive model for metastasis. These biomarkers may serve as potential therapeutic targets for future immunotherapy.

CD48 demonstrates consistent under-expression in T-lymphoblasts compared to mature T cells and NK cell cells, supporting its use as a reliable and informative marker for MRD detection in T-ALL. Its inclusion would enhance the accuracy of flow cytometry-based MRD panels.